Tobias Rüther
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tobias Rüther has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Rabenstein
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
6 shared publications Andrea Rabenstein
5 shared publications- Andreas Luch
Department of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany
3 shared publications Anil Batra
Sektion Suchtmedizin und Suchtforschung, Universitätsklinik für Psychiatrie und Psychotherapie Tübingen, Deutschland
3 shared publications- Elke Pieper
German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Max-Dohrn-Straße 8, 10589 Berlin, Germany
3 shared publications Oliver Pogarell
Department of Psychiatry und Psychotherapy, Ludwig Maximilian University, Munich, Germany
3 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Oxford University Press (OUP) in International Journal for Quality in Health Care
- Vol. 38 (4)
Failure mode and effects analysis of the in-hospital medication process: identification of systemic risks and development of improvement strategies
Background: Flaws in the in-hospital medication process compromise patient safety. A structured evaluation of the process using failure mode and effects analysis (FMEA) can identify and prioritize potential risks and help to develop targeted measures to improve medication safety. Methods: A prospective risk analysis using FMEA was conducted between February 2025 and February 2026 in a large tertiary care hospital by an interprofessional team including physicians, nurses, pharmacists, and a chief risk manager. In six structured workshops, the medication process was analyzed including admission, prescribing, order/delivery, dispensing, and discharge. Potential failure modes, their causes, and effects were identified based on expert experience and known errors from the hospitals critical incident reporting system. Each failure mode was independently rated for severity, occurrence, and detectability on a 5-point scale. Risk priority numbers (RPNs) were calculated to prioritize risks. Based on these results, targeted mitigation strategies were developed. Results: A total of 101 potential failure modes were identified, with the highest proportion in admission (n = 37; 36.6%). RPN values were moderate (median 22; interquartile ranges [IQR] 14–29; range 8–53). The highest ranked risks were missing drug interaction checks (RPN = 53) and lack of dose adjustment in renal impairment (RPN = 46). Additional high-risk areas included incomplete medication histories and communication deficits at process interfaces. Contributing factors were predominantly related to human and communication domains. Mitigation strategies included standardized medication reconciliation procedures, training programs for medical staff, pharmacist consultation service, and system-level interventions such as software improvements and improved communication processes. Conclusion: The FMEA identified specific risks within the in-hospital medication process. Furthermore, it revealed interdependencies between process stages and system-level vulnerabilities. The derived measures may contribute to improved medication safety across multiple stages of care in similar hospital settings. Future studies should evaluate their implementation and impact on medication errors.
- 5 October 2026
- Published by Oxford University Press (OUP) in International Journal for Quality in Health Care
- Vol. 38 (4)
Open AccessFailure mode and effects analysis of the in-hospital medication process: identification of systemic risks and development of improvement strategies
Background: Flaws in the in-hospital medication process compromise patient safety. A structured evaluation of the process using failure mode and effects analysis (FMEA) can identify and prioritize potential risks and help to develop targeted measures to improve medication safety. Methods: A prospective risk analysis using FMEA was conducted between February 2025 and February 2026 in a large tertiary care hospital by an interprofessional team including physicians, nurses, pharmacists, and a chief risk manager. In six structured workshops, the medication process was analyzed including admission, prescribing, order/delivery, dispensing, and discharge. Potential failure modes, their causes, and effects were identified based on expert experience and known errors from the hospitals critical incident reporting system. Each failure mode was independently rated for severity, occurrence, and detectability on a 5-point scale. Risk priority numbers (RPNs) were calculated to prioritize risks. Based on these results, targeted mitigation strategies were developed. Results: A total of 101 potential failure modes were identified, with the highest proportion in admission (n = 37; 36.6%). RPN values were moderate (median 22; interquartile ranges [IQR] 14–29; range 8–53). The highest ranked risks were missing drug interaction checks (RPN = 53) and lack of dose adjustment in renal impairment (RPN = 46). Additional high-risk areas included incomplete medication histories and communication deficits at process interfaces. Contributing factors were predominantly related to human and communication domains. Mitigation strategies included standardized medication reconciliation procedures, training programs for medical staff, pharmacist consultation service, and system-level interventions such as software improvements and improved communication processes. Conclusion: The FMEA identified specific risks within the in-hospital medication process. Furthermore, it revealed interdependencies between process stages and system-level vulnerabilities. The derived measures may contribute to improved medication safety across multiple stages of care in similar hospital settings. Future studies should evaluate their implementation and impact on medication errors.
- Open Access
- 1 October 2026
- Published by Hogrefe Publishing Group in SUCHT
- Vol. 72 (5) , 285-290
Kodex zum Umgang mit der Industrie, die abhängigkeitserzeugende Produkte vertreibt (z. B. Alkohol, Cannabis, Tabak, nicht pharmazeutische Nikotinprodukte, Glücksspiele, Sportwetten)
Zusammenfassung: Hintergrund: Industrien, deren Geschäftsmodell auf der Vermarktung abhängig machender oder gesundheitsschädlicher Produkte beruht, beeinflussen Forschung, Evidenzbildung und Gesundheitspolitik. Dazu zählen Tabak- und Nikotinindustrie, Alkohol- und Cannabisunternehmen sowie Glücksspiel- und Sportwettenanbieter, deren Strategien von industriefinanzierter Forschung über Sponsoring bis zu PR-Kampagnen und Lobbying reichen. Die vorliegenden Daten zeigen, dass dadurch systematische Interessenkonflikte entstehen, die wissenschaftliche Integrität und Glaubwürdigkeit gefährden. Position: Das Positionspapier formuliert einen Kodex für wissenschaftliche Fachgesellschaften im Umgang mit diesen Industrien. Es fordert die grundsätzliche Ablehnung von Geld- und Sachzuwendungen sowie wechselseitigen Gegenleistungen, die Vermeidung von Kooperationen mit industriegestützten Personen und Organisationen und eine konsequente Offenlegung aller relevanten finanziellen und nicht-finanziellen Interessenkonflikte der vergangenen fünf Jahre. Ausgenommen sind gesetzlich oder regulatorisch vorgeschriebene klinische Prüfungen unter Bedingungen strenger Transparenz, unabhängiger Governance und uneingeschränkter Publikationsrechte. Ziel ist es, Unabhängigkeit, Qualität und Vertrauenswürdigkeit der Suchtforschung zu sichern und den Einfluss kommerzieller Interessen auf Forschung, Lehre und gesundheitspolitische Empfehlungen wirksam zu begrenzen.
- 1 October 2026
- Published by Hogrefe Publishing Group in SUCHT
- Vol. 72 (5) , 285-290
Open AccessKodex zum Umgang mit der Industrie, die abhängigkeitserzeugende Produkte vertreibt (z. B. Alkohol, Cannabis, Tabak, nicht pharmazeutische Nikotinprodukte, Glücksspiele, Sportwetten)
Zusammenfassung: Hintergrund: Industrien, deren Geschäftsmodell auf der Vermarktung abhängig machender oder gesundheitsschädlicher Produkte beruht, beeinflussen Forschung, Evidenzbildung und Gesundheitspolitik. Dazu zählen Tabak- und Nikotinindustrie, Alkohol- und Cannabisunternehmen sowie Glücksspiel- und Sportwettenanbieter, deren Strategien von industriefinanzierter Forschung über Sponsoring bis zu PR-Kampagnen und Lobbying reichen. Die vorliegenden Daten zeigen, dass dadurch systematische Interessenkonflikte entstehen, die wissenschaftliche Integrität und Glaubwürdigkeit gefährden. Position: Das Positionspapier formuliert einen Kodex für wissenschaftliche Fachgesellschaften im Umgang mit diesen Industrien. Es fordert die grundsätzliche Ablehnung von Geld- und Sachzuwendungen sowie wechselseitigen Gegenleistungen, die Vermeidung von Kooperationen mit industriegestützten Personen und Organisationen und eine konsequente Offenlegung aller relevanten finanziellen und nicht-finanziellen Interessenkonflikte der vergangenen fünf Jahre. Ausgenommen sind gesetzlich oder regulatorisch vorgeschriebene klinische Prüfungen unter Bedingungen strenger Transparenz, unabhängiger Governance und uneingeschränkter Publikationsrechte. Ziel ist es, Unabhängigkeit, Qualität und Vertrauenswürdigkeit der Suchtforschung zu sichern und den Einfluss kommerzieller Interessen auf Forschung, Lehre und gesundheitspolitische Empfehlungen wirksam zu begrenzen.
- Open Access
- 3 September 2026
- Published by Springer Nature in Community Mental Health Journal
- p. 1-13
Sexual Health in Psychiatry: Bridging the Communication Gap and Training Needs between Patients and Clinicians – A Cross-Sectional Exploratory Pilot Study
Sexual health is integral to mental well-being, yet it remains under-addressed in psychiatric care. Mental disorders and psychotropic medications can cause sexual dysfunctions. Despite its clinical relevance, sexual health is often not routinely assessed or discussed in psychiatric assessment and treatment, possibly due to insufficient training, stigma, and clinicians’ uncertainty. This pilot study examined how sexuality is addressed in psychiatric treatment and how relevant the topic is perceived, integrating patient and clinician perspectives. A cross-sectional, anonymous online survey was conducted between February and July 2025 in two German academic psychiatric hospitals. Psychiatric patients and mental-health professionals completed questionnaires tailored to their perspectives. Patients completed measures of sexual functioning, well-being, and communication about sexuality, whereas mental-health professionals completed measures of attitudes, clinical practice, and professional training. Data were analysed using descriptive and inferential statistics. A total of 231 patients and 194 clinicians participated. Nearly all patients reported at least one sexual dysfunction (100% women, 97% men), while only 18.7% reported being sexually satisfied. Although most patients (62.0%) considered sexuality an important topic, only 12.5% reported that it had been addressed. Clinicians reported addressing sexuality more frequently (psychotherapists: 44.0%; specialists: 62.1%). Among physicians, confidence and years of professional experience predicted actively discussing sexual issues ( p = .013). More than 80% of clinicians reported insufficient coverage of sexual health during their education. Sexual health remains a neglected domain in psychiatric care despite being recognized as important by both patients and clinicians. Strengthening clinicians’ confidence through targeted training, routine screening, and institutional support may help normalize the assessment of sexual health as part of holistic, patient-centred psychiatric care.
- 3 September 2026
- Published by Springer Nature in Community Mental Health Journal
- p. 1-13
Open AccessSexual Health in Psychiatry: Bridging the Communication Gap and Training Needs between Patients and Clinicians – A Cross-Sectional Exploratory Pilot Study
Sexual health is integral to mental well-being, yet it remains under-addressed in psychiatric care. Mental disorders and psychotropic medications can cause sexual dysfunctions. Despite its clinical relevance, sexual health is often not routinely assessed or discussed in psychiatric assessment and treatment, possibly due to insufficient training, stigma, and clinicians’ uncertainty. This pilot study examined how sexuality is addressed in psychiatric treatment and how relevant the topic is perceived, integrating patient and clinician perspectives. A cross-sectional, anonymous online survey was conducted between February and July 2025 in two German academic psychiatric hospitals. Psychiatric patients and mental-health professionals completed questionnaires tailored to their perspectives. Patients completed measures of sexual functioning, well-being, and communication about sexuality, whereas mental-health professionals completed measures of attitudes, clinical practice, and professional training. Data were analysed using descriptive and inferential statistics. A total of 231 patients and 194 clinicians participated. Nearly all patients reported at least one sexual dysfunction (100% women, 97% men), while only 18.7% reported being sexually satisfied. Although most patients (62.0%) considered sexuality an important topic, only 12.5% reported that it had been addressed. Clinicians reported addressing sexuality more frequently (psychotherapists: 44.0%; specialists: 62.1%). Among physicians, confidence and years of professional experience predicted actively discussing sexual issues ( p = .013). More than 80% of clinicians reported insufficient coverage of sexual health during their education. Sexual health remains a neglected domain in psychiatric care despite being recognized as important by both patients and clinicians. Strengthening clinicians’ confidence through targeted training, routine screening, and institutional support may help normalize the assessment of sexual health as part of holistic, patient-centred psychiatric care.
- Open Access
- 18 April 2026
- Published by Springer Nature in BMC Health Services Research
- Vol. 26 (1)
Unintended medication discrepancies across key stages of the in-hospital medication process: a retrospective real-world study in hospitalized patients
Background: The in-hospital medication process is vulnerable to medication errors, especially during care transitions, when medication discrepancies occur most frequently. However, previous studies focused only on medication errors at single points in this process. This study therefore investigated key stages of the medication process. Also, we examined potential risk factors for unintended medication discrepancies (UMDs) at admission. Methods: A single-center retrospective study was conducted on seven reference wards from different medical specialties. Technical UMDs at admission, intra-hospital transfer, dispensing, and discharge were evaluated and categorized for patients hospitalized on two predefined days in November 2023. Potential risk factors for UMDs at admission were analyzed using descriptive statistics and logistic regression. Results: During the study period, 449 UMDs were identified in 215 patients (Median 1 per patient, range 0–15). Of these, 150 (33.4%) were classified in their potential clinical relevance as low severity, 157 (35.0%) as medium, and 142 (31.6%) as severe. The majority of UMDs (206; 45.9%) occurred at admission, of which 104 (50.5%) were still present in discharge letters. Changes in clinical parameters (blood pressure, oxygen saturation, hyper/hypoglycemia) were associated with 37 (18.0%) UMDs for 27 patients at admission. During intra-hospital transfers, 49 UMDs (10.9%) were detected, 4 between general wards and 45 between general and intensive care units. A total of 90 UMDs (20.0%) were identified during dispensing and 104 (23.2%) at discharge.The multivariable logistic regression showed that patients with ≥10 drugs had an increased risk of UMDs at admission (OR 4.0; 95% CI 1.767–9.277; p < 0.004). Medication histories taken by pharmacists were associated with reduced UMDs at admission (OR 0.13; 95% CI 0.042–0.414; p < 0.001) compared to ward staff. Discussion: Our findings demonstrate that UMDs are frequent across the hospital pathway, with admission as the most vulnerable point. Taking ≥ 10 drugs was a risk factor, while pharmacist-led medication histories reduced the occurrence of UMDs, highlighting the importance of structured reconciliation. By covering admission, transfers, dispensing, and discharge in a cohort, this study provides a comprehensive perspective on medication process, emphasizing the need for targeted interventions during hospitalization and discharge.
- 18 April 2026
- Published by Springer Nature in BMC Health Services Research
- Vol. 26 (1)
Open AccessUnintended medication discrepancies across key stages of the in-hospital medication process: a retrospective real-world study in hospitalized patients
Background: The in-hospital medication process is vulnerable to medication errors, especially during care transitions, when medication discrepancies occur most frequently. However, previous studies focused only on medication errors at single points in this process. This study therefore investigated key stages of the medication process. Also, we examined potential risk factors for unintended medication discrepancies (UMDs) at admission. Methods: A single-center retrospective study was conducted on seven reference wards from different medical specialties. Technical UMDs at admission, intra-hospital transfer, dispensing, and discharge were evaluated and categorized for patients hospitalized on two predefined days in November 2023. Potential risk factors for UMDs at admission were analyzed using descriptive statistics and logistic regression. Results: During the study period, 449 UMDs were identified in 215 patients (Median 1 per patient, range 0–15). Of these, 150 (33.4%) were classified in their potential clinical relevance as low severity, 157 (35.0%) as medium, and 142 (31.6%) as severe. The majority of UMDs (206; 45.9%) occurred at admission, of which 104 (50.5%) were still present in discharge letters. Changes in clinical parameters (blood pressure, oxygen saturation, hyper/hypoglycemia) were associated with 37 (18.0%) UMDs for 27 patients at admission. During intra-hospital transfers, 49 UMDs (10.9%) were detected, 4 between general wards and 45 between general and intensive care units. A total of 90 UMDs (20.0%) were identified during dispensing and 104 (23.2%) at discharge.The multivariable logistic regression showed that patients with ≥10 drugs had an increased risk of UMDs at admission (OR 4.0; 95% CI 1.767–9.277; p < 0.004). Medication histories taken by pharmacists were associated with reduced UMDs at admission (OR 0.13; 95% CI 0.042–0.414; p < 0.001) compared to ward staff. Discussion: Our findings demonstrate that UMDs are frequent across the hospital pathway, with admission as the most vulnerable point. Taking ≥ 10 drugs was a risk factor, while pharmacist-led medication histories reduced the occurrence of UMDs, highlighting the importance of structured reconciliation. By covering admission, transfers, dispensing, and discharge in a cohort, this study provides a comprehensive perspective on medication process, emphasizing the need for targeted interventions during hospitalization and discharge.
- Open Access
Smoking Topography, Nicotine Kinetics, and Subjective Smoking Experience of Mentholated and Non-Mentholated Heated Tobacco Products in Occasional Smokers
Background: Heated tobacco products (HTPs) are marketed as reduced-harm alternatives to conventional cigarettes (CCs) and are increasingly used by young adults and occasional smokers. However, their acute nicotine delivery and user experience remain insufficiently studied in occasional smokers without established cigarette or nicotine dependence. Additives such as menthol—known to reduce sensory irritation and facilitate inhalation—may further influence initiation and product appeal, particularly in naïve users. Methods: In a crossover study with three separate study days, n = 15 occasional smokers without established cigarette or nicotine dependence consumed a mentholated HTP (mHTP), a non-mentholated HTP (nmHTP), and a conventional cigarette (CC) under ad libitum conditions during a 30 min observation. We measured plasma nicotine concentrations, smoking topography, cardiovascular parameters, and subjective effects (mCEQ). Results: Nicotine pharmacokinetics (Cmax, AUC) were comparable across products (Cmax 7.8–8.5 ng/mL; AUC 2.3–2.8 ng·min/mL [geometric means]; no significant differences), even though participants had no prior experience with HTPs. Compared to CCs, HTPs were associated with longer puff durations (2.09 s mHTP/2.00 s nmHTP vs. 1.78 s CC), higher puff volumes (mean: 68.06/68.16 vs. 43.76 mL; total: 949.80/897.73 vs. 522.41 mL), and greater flow rates (mean 37.49/38.25 vs. 27.68 mL/s; peak 63.24/63.69 vs. 44.38 mL/s). Subjective effects did not differ significantly between products (mCEQ subscale examples: satisfaction 3.00–3.33/7; reward 2.81–3.31/7; craving reduction 5.07–5.60/7). Cardiovascular parameters such as heart rate or systolic blood pressure showed with no between-product differences (HR p = 0.518; SBP p = 0.109) and no differences in their change over time between products (HR p = 0.807; SBP p = 0.734). No differences were observed between mHTP and nmHTP. Conclusion: HTPs can deliver nicotine and evoke user experiences similar to CCs, even in non-dependent users. The more intensive inhalation behavior observed with HTPs may reflect compensatory use and merits further investigation. Although no menthol-specific effects were observed, methodological constraints may have limited their detectability.
Open AccessSmoking Topography, Nicotine Kinetics, and Subjective Smoking Experience of Mentholated and Non-Mentholated Heated Tobacco Products in Occasional Smokers
Background: Heated tobacco products (HTPs) are marketed as reduced-harm alternatives to conventional cigarettes (CCs) and are increasingly used by young adults and occasional smokers. However, their acute nicotine delivery and user experience remain insufficiently studied in occasional smokers without established cigarette or nicotine dependence. Additives such as menthol—known to reduce sensory irritation and facilitate inhalation—may further influence initiation and product appeal, particularly in naïve users. Methods: In a crossover study with three separate study days, n = 15 occasional smokers without established cigarette or nicotine dependence consumed a mentholated HTP (mHTP), a non-mentholated HTP (nmHTP), and a conventional cigarette (CC) under ad libitum conditions during a 30 min observation. We measured plasma nicotine concentrations, smoking topography, cardiovascular parameters, and subjective effects (mCEQ). Results: Nicotine pharmacokinetics (Cmax, AUC) were comparable across products (Cmax 7.8–8.5 ng/mL; AUC 2.3–2.8 ng·min/mL [geometric means]; no significant differences), even though participants had no prior experience with HTPs. Compared to CCs, HTPs were associated with longer puff durations (2.09 s mHTP/2.00 s nmHTP vs. 1.78 s CC), higher puff volumes (mean: 68.06/68.16 vs. 43.76 mL; total: 949.80/897.73 vs. 522.41 mL), and greater flow rates (mean 37.49/38.25 vs. 27.68 mL/s; peak 63.24/63.69 vs. 44.38 mL/s). Subjective effects did not differ significantly between products (mCEQ subscale examples: satisfaction 3.00–3.33/7; reward 2.81–3.31/7; craving reduction 5.07–5.60/7). Cardiovascular parameters such as heart rate or systolic blood pressure showed with no between-product differences (HR p = 0.518; SBP p = 0.109) and no differences in their change over time between products (HR p = 0.807; SBP p = 0.734). No differences were observed between mHTP and nmHTP. Conclusion: HTPs can deliver nicotine and evoke user experiences similar to CCs, even in non-dependent users. The more intensive inhalation behavior observed with HTPs may reflect compensatory use and merits further investigation. Although no menthol-specific effects were observed, methodological constraints may have limited their detectability.
- 8 May 2025
- Published by Georg Thieme Verlag KG in PSYCH up2date
- Vol. 19 (03) , 217-234
Neue Konsumformen von Nikotin
Neue Nikotinprodukte wie E-Zigaretten, Heated-Tobacco-Produkte (HTP) und Nikotinpouches verändern den Markt rasant und gewinnen an Beliebtheit. Obwohl diese Produkte oft als „harmlose“ Alternativen zur konventionellen Zigarette vermarktet werden, bergen sie gesundheitliche Risiken und stellen eine Herausforderung für die öffentliche Gesundheit dar. Article published online: 08 May 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 8 May 2025
- Published by Georg Thieme Verlag KG in PSYCH up2date
- Vol. 19 (03) , 217-234
Neue Konsumformen von Nikotin
Neue Nikotinprodukte wie E-Zigaretten, Heated-Tobacco-Produkte (HTP) und Nikotinpouches verändern den Markt rasant und gewinnen an Beliebtheit. Obwohl diese Produkte oft als „harmlose“ Alternativen zur konventionellen Zigarette vermarktet werden, bergen sie gesundheitliche Risiken und stellen eine Herausforderung für die öffentliche Gesundheit dar. Article published online: 08 May 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 1 April 2025
- Published by Hogrefe Publishing Group in SUCHT
- Vol. 71 (2) , 87-92
Guideline on the Treatment of General Internet Use Disorder
Aim: This guideline provides evidence-based recommendations for the treatment of General Internet Use Disorder (IUD), a behavioural addiction characterized by excessive and compulsive internet use. General IUD is prevalent, particularly among younger individuals, with varying rates across different age groups. Methods: Due to the relatively young research field and the limited evidence available in certain areas, the methodology of an S1 guideline was chosen. However, where possible, a systematic literature review was conducted, bringing the methodology closer to that of an S2e guideline. Results: The guideline prioritizes Cognitive-Behavioural Therapy (CBT) as the main treatment approach for General Internet Use Disorder (IUD), demonstrating effectiveness in both individual and group formats. In addition to CBT, other interventions such as combining CBT with electroacupuncture, using pharmacotherapy (e. g., bupropion), applying relaxation techniques (e. g., Qigong), engaging in physical activities (e. g., sports), and offering solution-focused group counselling are also recommended to help manage symptoms and enhance mental well-being. For children and adolescents, the guideline suggests school-based and family-centered interventions, focusing on psychoeducation, goal setting, and fostering a supportive environment for healthier internet use. Joint treatment of patients with various IUD subtypes in group settings is recommended to optimize care and address the chronic nature of the disorder. Conclusion: These recommendations aim to guide clinicians in effectively managing general IUD and improving patient outcomes.
- 1 April 2025
- Published by Hogrefe Publishing Group in SUCHT
- Vol. 71 (2) , 87-92
Guideline on the Treatment of General Internet Use Disorder
Aim: This guideline provides evidence-based recommendations for the treatment of General Internet Use Disorder (IUD), a behavioural addiction characterized by excessive and compulsive internet use. General IUD is prevalent, particularly among younger individuals, with varying rates across different age groups. Methods: Due to the relatively young research field and the limited evidence available in certain areas, the methodology of an S1 guideline was chosen. However, where possible, a systematic literature review was conducted, bringing the methodology closer to that of an S2e guideline. Results: The guideline prioritizes Cognitive-Behavioural Therapy (CBT) as the main treatment approach for General Internet Use Disorder (IUD), demonstrating effectiveness in both individual and group formats. In addition to CBT, other interventions such as combining CBT with electroacupuncture, using pharmacotherapy (e. g., bupropion), applying relaxation techniques (e. g., Qigong), engaging in physical activities (e. g., sports), and offering solution-focused group counselling are also recommended to help manage symptoms and enhance mental well-being. For children and adolescents, the guideline suggests school-based and family-centered interventions, focusing on psychoeducation, goal setting, and fostering a supportive environment for healthier internet use. Joint treatment of patients with various IUD subtypes in group settings is recommended to optimize care and address the chronic nature of the disorder. Conclusion: These recommendations aim to guide clinicians in effectively managing general IUD and improving patient outcomes.
- 1 February 2025
- Published by Hogrefe Publishing Group in SUCHT
- Vol. 71 (1) , 39-46
Komm kuscheln – Serumoxytozinkonzentration als potenzieller Biomarker bei Chemsex-Usern
Zusammenfassung: Hintergrund: Das Phänomen Chemsex wird sowohl gesellschaftlich als auch klinisch immer relevanter. Ein suffizienter Therapieansatz sowie biologische Erklärungsansätze sind aktuell nicht etabliert und dringend erforderlich. Dem Hormon Oxytocin wird eine Schlüsselrolle bei sozialer Bindung und Sexualität zugesprochen. Ziel: Ziel der Studie war es, den Zusammenhang zwischen Serum-Oxytocinspiegeln und Chemsex-Konsummuster im Sinne einer Pilotstudie zu charakterisieren, um ggf. diagnostische und therapeutische Konsequenzen ableiten zu können. Methodik: Es wurde bei Chemsex-Usern und Kontrollprobanden die Serumkonzentration von Oxytocin mittels ELISA und anschließender photometrischer Messung bestimmt. Eingeschlossen wurden Männer, die Sex mit Männern haben (MSM). Die Oxytocinkonzentration wurde mittels ANOVA und Post-Hoc t-Test verglichen. Ergebnisse: 30 Chemsex-User und 31 nach Alter und Bildungsgrad vergleichbare Kontrollprobanden wurden verglichen. Es zeigte sich eine signifikant reduzierte Oxytocinkonzentration bei der Gruppe der Chemsex-User (187.91 pg/ml [+ 80.98, 90.36–425.1]) im Vergleich zu Kontrollprobanden (286.86 pg/ml [+160.86, 103.0–716.0]). Messungsbedingte Einflussgrößen wurden berücksichtigt. Schlussfolgerungen: Es zeigte sich eine signifikant reduzierte Serumoxytocinkonzentration bei Chemsex-Usern im Vergleich zu MSM-Kontrollprobanden. Relevante Einflussfaktoren sowie die Notwendigkeit weiterer Forschung zum Thema werden diskutiert.
- 1 February 2025
- Published by Hogrefe Publishing Group in SUCHT
- Vol. 71 (1) , 39-46
Komm kuscheln – Serumoxytozinkonzentration als potenzieller Biomarker bei Chemsex-Usern
Zusammenfassung: Hintergrund: Das Phänomen Chemsex wird sowohl gesellschaftlich als auch klinisch immer relevanter. Ein suffizienter Therapieansatz sowie biologische Erklärungsansätze sind aktuell nicht etabliert und dringend erforderlich. Dem Hormon Oxytocin wird eine Schlüsselrolle bei sozialer Bindung und Sexualität zugesprochen. Ziel: Ziel der Studie war es, den Zusammenhang zwischen Serum-Oxytocinspiegeln und Chemsex-Konsummuster im Sinne einer Pilotstudie zu charakterisieren, um ggf. diagnostische und therapeutische Konsequenzen ableiten zu können. Methodik: Es wurde bei Chemsex-Usern und Kontrollprobanden die Serumkonzentration von Oxytocin mittels ELISA und anschließender photometrischer Messung bestimmt. Eingeschlossen wurden Männer, die Sex mit Männern haben (MSM). Die Oxytocinkonzentration wurde mittels ANOVA und Post-Hoc t-Test verglichen. Ergebnisse: 30 Chemsex-User und 31 nach Alter und Bildungsgrad vergleichbare Kontrollprobanden wurden verglichen. Es zeigte sich eine signifikant reduzierte Oxytocinkonzentration bei der Gruppe der Chemsex-User (187.91 pg/ml [+ 80.98, 90.36–425.1]) im Vergleich zu Kontrollprobanden (286.86 pg/ml [+160.86, 103.0–716.0]). Messungsbedingte Einflussgrößen wurden berücksichtigt. Schlussfolgerungen: Es zeigte sich eine signifikant reduzierte Serumoxytocinkonzentration bei Chemsex-Usern im Vergleich zu MSM-Kontrollprobanden. Relevante Einflussfaktoren sowie die Notwendigkeit weiterer Forschung zum Thema werden diskutiert.
- Open Access
- 29 June 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 666
“I Can’t Get No Satisfaction”—Psychosocial Aspects and Awareness of Negative Impacts in Chemsex Users: Results from an Anonymous Online Survey
Chemsex is the interplay of substance use by men who have sex with men (MSM) in sexual contexts. The minority stress model and the identity process theory are explanatory models. In this study, we investigated whether (i) differences in certain psychosocial aspects (i.e., shame, aspects of queer identity, and sexual self-concepts) exist between chemsex users and non-users, and (ii) which factors influence an awareness of negative impacts in chemsex users. We conducted an anonymous, cross-sectional, online survey, including sociodemography, sexual history, history of substance use, validated scales for shame-proneness, aspects of queer identity, and sexual self-concepts. Our analysis comprised descriptive statistics, t-tests, Spearman’s correlations, and a multiple linear regression model. We recorded a total of 3257 datasets with 107 chemsex users. Chemsex users showed higher rates for risky sexual behavior. Values for shame proneness, more negative aspects of queer identity, and sexual self-concepts were elevated in chemsex users with an awareness of negative impacts. Sexual anxiety, intravenous substance use, and having had a difficult process coming out were significant predictors of feeling negative impacts. Aspects of shame, queer identity aspects, and sexual self-concepts play an important role in the field of chemsex. Different explanatory models seem to be relevant for different subgroups of chemsex users. Chemsex users with an awareness of a problem were particularly vulnerable and distressed but had the highest motivation for change. Prevention, counseling, and care might profit from the inclusion of these aspects. Further anti-stigma campaigns and a specialization of the healthcare system are needed. Registration: DRKS00022336, date: 29th of October, 2020.
- 29 June 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 666
Open Access“I Can’t Get No Satisfaction”—Psychosocial Aspects and Awareness of Negative Impacts in Chemsex Users: Results from an Anonymous Online Survey
Chemsex is the interplay of substance use by men who have sex with men (MSM) in sexual contexts. The minority stress model and the identity process theory are explanatory models. In this study, we investigated whether (i) differences in certain psychosocial aspects (i.e., shame, aspects of queer identity, and sexual self-concepts) exist between chemsex users and non-users, and (ii) which factors influence an awareness of negative impacts in chemsex users. We conducted an anonymous, cross-sectional, online survey, including sociodemography, sexual history, history of substance use, validated scales for shame-proneness, aspects of queer identity, and sexual self-concepts. Our analysis comprised descriptive statistics, t-tests, Spearman’s correlations, and a multiple linear regression model. We recorded a total of 3257 datasets with 107 chemsex users. Chemsex users showed higher rates for risky sexual behavior. Values for shame proneness, more negative aspects of queer identity, and sexual self-concepts were elevated in chemsex users with an awareness of negative impacts. Sexual anxiety, intravenous substance use, and having had a difficult process coming out were significant predictors of feeling negative impacts. Aspects of shame, queer identity aspects, and sexual self-concepts play an important role in the field of chemsex. Different explanatory models seem to be relevant for different subgroups of chemsex users. Chemsex users with an awareness of a problem were particularly vulnerable and distressed but had the highest motivation for change. Prevention, counseling, and care might profit from the inclusion of these aspects. Further anti-stigma campaigns and a specialization of the healthcare system are needed. Registration: DRKS00022336, date: 29th of October, 2020.
- Open Access
- 13 November 2023
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (4) , 1001-1011
Transcranial direct current stimulation combined with a brief intervention for smoking cessation: a randomized double-blind clinical trial
Non-invasive brain stimulation methods are currently being evaluated for treatment of addictive disorders. Some evidence indicates that modulating left and right prefrontal brain activity by transcranial direct current stimulation (tDCS) can reduce craving and relapse rates in tobacco addiction. Therefore, this study investigated the effects of active and sham tDCS as an add-on treatment to a standardized brief intervention for smoking cessation. This randomized, double-blind study included 36 participants (22 women and 14 men) with nicotine dependence according to ICD-10 criteria. At five visits on alternate days, participants underwent a 20-min active or sham tDCS over the left dorsolateral prefrontal cortex and subsequently participated in a 10-min brief intervention for smoking cessation. Patients were followed up after 3 months. On each treatment day and at follow-up, abstinence was assessed as the smoking status nonsmoker and craving was assessed with the German version of the Questionnaire on Smoking Urges. At each visit, the number of cigarettes smoked per day was recorded and carbon monoxide in expired air and cotinine in saliva were measured. At follow-up, a study-specific questionnaire was used to assess tobacco use. All 36 participants completed the treatment sessions, but one participant in each group was lost to follow-up. Abstinence rates were not significantly different between the groups at any of the study visits, but craving was significantly lower in the active group at tDCS session 5 compared with session 1. tDCS combined with a brief intervention may support smoking cessation, but studies need to evaluate whether longer and more intensive treatment can achieve significant, sustainable effects.
- 13 November 2023
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 274 (4) , 1001-1011
Open AccessTranscranial direct current stimulation combined with a brief intervention for smoking cessation: a randomized double-blind clinical trial
Non-invasive brain stimulation methods are currently being evaluated for treatment of addictive disorders. Some evidence indicates that modulating left and right prefrontal brain activity by transcranial direct current stimulation (tDCS) can reduce craving and relapse rates in tobacco addiction. Therefore, this study investigated the effects of active and sham tDCS as an add-on treatment to a standardized brief intervention for smoking cessation. This randomized, double-blind study included 36 participants (22 women and 14 men) with nicotine dependence according to ICD-10 criteria. At five visits on alternate days, participants underwent a 20-min active or sham tDCS over the left dorsolateral prefrontal cortex and subsequently participated in a 10-min brief intervention for smoking cessation. Patients were followed up after 3 months. On each treatment day and at follow-up, abstinence was assessed as the smoking status nonsmoker and craving was assessed with the German version of the Questionnaire on Smoking Urges. At each visit, the number of cigarettes smoked per day was recorded and carbon monoxide in expired air and cotinine in saliva were measured. At follow-up, a study-specific questionnaire was used to assess tobacco use. All 36 participants completed the treatment sessions, but one participant in each group was lost to follow-up. Abstinence rates were not significantly different between the groups at any of the study visits, but craving was significantly lower in the active group at tDCS session 5 compared with session 1. tDCS combined with a brief intervention may support smoking cessation, but studies need to evaluate whether longer and more intensive treatment can achieve significant, sustainable effects.